Overview

A Study of JNJ-56136379 in Healthy Participants

Status:
Withdrawn

Trial end date:
2021-07-30

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the effect of multiple-dose JNJ-56136379 on the single-dose pharmacokinetics (PK) of the combination of bictegravir (BIC), emtricitabine (FTC), tenofovir alafenamide (TAF) in healthy adult participants.

Phase:

Phase 1

Details

Lead Sponsor:

Janssen Research & Development, LLC

Treatments:

Emtricitabine
Tenofovir